Patents Assigned to Universite de Montpellier
-
Patent number: 11649210Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:Type: GrantFiled: August 17, 2020Date of Patent: May 16, 2023Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau, Romain Najman
-
Publication number: 20230106420Abstract: A compound of formula (I) is: wherein: X2 represents a —CO—NRk— group, a —NR?k—CO— group, a —O— group, a —CO— group, a —SO2-group, a —CS—NH— group, a —CH2—NH—, a group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C5-C11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C1-C4)alkenyl group, a —PO(ORa)(ORb) group, a 5-membered heteroaromatic ring or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.Type: ApplicationFiled: July 17, 2020Publication date: April 6, 2023Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Florence MAHUTEAU, Romain NAJMAN, Jamal TAZI, Julien SANTO, Cécile APOLIT, Frederic LABEGUERE, Brice SAUTIER, Natacha BIENVENU, Elisa AZZALI
-
Publication number: 20230067676Abstract: Co-crystals and pharmaceutically acceptable salts and methods for the preparation of the co-crystals and the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, pharmaceutical compositions including them as well as their use as medicines and more particularly for use in the prevention and/or treatment of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.Type: ApplicationFiled: January 29, 2021Publication date: March 2, 2023Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jérôme MENEGOTTO, Jérôme DENIS
-
Publication number: 20230066255Abstract: A medical analysis device with cellular impedance signal processing comprises a memory (4) arranged to receive pulse data sets, each pulse data set comprising impedance value data that are associated each time with a time marker, these data together representing a curve of cellular impedance values that are measured as a cell passes through a polarised opening. This device further comprises a classifier (6) comprising a convolutional neural network receiving the pulse data sets as input and is provided with at least one convolutional layer, which convolutional layer has a depth greater than or equal to 3, and at least two fully connected layers, in addition to an output layer rendering a cell classification from which a pulse data set is derived.Type: ApplicationFiled: January 15, 2021Publication date: March 2, 2023Applicants: HORIBA ABX SAS, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Pierre TARACONAT, Damien ISEBE, Simon MENDEZ, Franck NICOUD
-
Patent number: 11584943Abstract: The invention relates to a process for the recovery of CO2 by biological reduction comprising a step of bringing a liquid phase containing the bacterium Stenotrophomonas maltophilia into contact with a CO2-containing gas phase under conditions allowing the production of formate and/or methane from said CO2. The process according to the invention can be implemented in particular in a closed reactor or a semi-closed reactor or a continuous reactor, electrochemically assisted or not.Type: GrantFiled: June 4, 2019Date of Patent: February 21, 2023Assignees: UNIVERSITÉ DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Laurence Soussan, Azariel Ruiz-Valencia, Djahida Benmeziane, José Sanchez-Marcano, Marie-Pierre Belleville, Delphine Paolucci-Jeanjean
-
Patent number: 11577112Abstract: A method for destructing and valorizing an asbestos waste including the steps of: determining the asbestos mineralogical group contained in the waste, performing a treatment on the waste which includes of: an acid treatment when the waste comprises only a chrysotile, a base treatment when the waste comprises only an amphibole, the acid treatment followed by the base treatment when the asbestos waste includes a mixture of a chrysotile and an amphibole, and valorizing at least one of the products obtained on completion of the performing of the treatment. An embodiment also concerns a treatment of a chrysotile waste through an acid treatment followed by a thermal treatment.Type: GrantFiled: August 21, 2018Date of Patent: February 14, 2023Assignees: UNIVERSITÉ DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ENSCM—ECOLE NATIONALE SUPERIEURE DE CHIMIEInventors: Gaël Talbi, Olivier Cambon, Martine Cambon
-
Patent number: 11578369Abstract: A method for in vitro predicting of the outcome of an individual having a multiple myeloma, including the steps of: a) measuring the expression level of at least 5 genes and/or proteins encoded by the 5 genes, the genes being selected in a group including NRP2, REEP1, SV2B, ARRB1, CACNA1G, FBLIM1, FGFR1, IRF6, ITGA9, NOVA2, PPP2R2C, SLC5A1, SORL1, SYT7 and THY1, in a biological sample obtained from the individual; b) calculating a score value from the expression level obtained at step a); c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.Type: GrantFiled: October 31, 2017Date of Patent: February 14, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Jérôme Moreaux, Laurie Herviou, Alboukadel Kassambara, Giacomo Cavalli
-
Patent number: 11573240Abstract: Disclosed are methods for diagnosing CAT1-related diseases, wherein the methods include detecting CAT1 in a cell by a BLV.RBD ligand, or a variant or a fragment thereof. Also disclosed is a BLV.RBD ligand, or a variant or a fragment thereof for use in the treatment of CAT1-related diseases and/or BLV infections.Type: GrantFiled: November 18, 2016Date of Patent: February 7, 2023Assignees: METAFORA BIOSYSTEMS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, UNIVERSITÉ PARIS CITÉInventors: Svilena Ivanova, Donatella Giovannini, Julien Bellis, Jawida Lezaar, Vincent Petit, Jean-Luc Battini, Marc Sitbon, Valérie Courgnaud
-
Patent number: 11562050Abstract: An integrated circuit includes: one or more protected circuits; a license control circuit configured to request, from a license issuer, a license for activating the one or more protected circuits, the license request having a seed value; and a cryptographic circuit configured to verify the authenticity of a license received from the license issuer based on the seed value, wherein the license control circuit is configured to impose a validity limit on the received license, and to request a new license from the license issuer before the validity limit of the received license.Type: GrantFiled: December 7, 2018Date of Patent: January 24, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Université de Montpellier, ALGODONEInventors: Lionel Torres, Jérôme Rampon, Gaël Paul
-
Patent number: 11541023Abstract: The invention relates to compounds exhibiting kallikrein inhibitory activity, and to compositions comprising at least one of these compounds for use in the treatment of diseases or disorders in which kallikrein activity is dysregulated, particularly neurodegenerative and inflammatory diseases.Type: GrantFiled: February 13, 2019Date of Patent: January 3, 2023Assignees: SARBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE, UNIVERSITÉ DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Chahrazade El Amri, Feryel Soualmia, Nicolas Masurier, Sabrina Aït Amiri, Brahim Nait Oumesmar, Cyrille Deboux
-
Publication number: 20220396840Abstract: The invention relates to the use of an iron-score based on the expression level of at least 1 gene, in particular at least 3, preferably at least 5, and even preferably 8 genes selected in the group consisting of APEX1, TFRC, HIF1A, ABCG2, SCARA3, IREB2, SFXN4 and SLC39A14 involved in the iron metabolism, as a prognosis marker in subjects having MCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.Type: ApplicationFiled: November 6, 2020Publication date: December 15, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jérôme MOREAUX, Raphaël RODRIGUEZ, Julie DEVIN, Caroline BRET, Tatiana CANEQUE COBO
-
Patent number: 11525826Abstract: The present invention relates to the field of biological diagnosis in oncology. It relates to a method and apparatus for detecting and/or characterizing tumor cells by detecting one or more elements of the tumor cell secretome, in particular one or more peptides or proteins, and, in particular, one or more tumor markers. The invention also relates to detecting and/or characterizing droplets of tumor cells and their method of preparation.Type: GrantFiled: April 18, 2017Date of Patent: December 13, 2022Assignees: Chu Montpellier, Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris, Centre National De La Recherche Scientifique, Université De Montpellier, Axlr, Satt Du Languedoc RoussillonInventors: Catherine Michèle Marilou Alix-Panabieres, Andrew David Griffiths, Raphaël Clément Li-Ming Doineau, Clément Nizak, Philippe Chi-Thanh Nghe, Jean-Marie Pierre Baudry, Elodie Michèle Christine Brient-Litzler, Klaus Eyer, Jérôme Bibette
-
Patent number: 11499197Abstract: The invention relates to a method for in vitro predicting the outcome of an individual having a multiple myeloma, comprising the steps of: a. measuring the expression level of genes coding for kinases, b. calculating a score value for each genes; and c. classifying the individual as having a good or a bad outcome.Type: GrantFiled: October 30, 2018Date of Patent: November 15, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIERInventors: Jerome Moreaux, Hugues De Boussac, Alboukadel Kassambara
-
Publication number: 20220356175Abstract: A compound of formula (Ic) wherein X2 represents a —CO—NRk— group, wherein Rk represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH2)s—O—, a —CO— group, a —SO2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, —a NH—SO2— or a —SO2—NH— group; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a a group, a group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.Type: ApplicationFiled: July 9, 2019Publication date: November 10, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Publication number: 20220357326Abstract: A method for quantifying the activity of the proteins/enzymes involved in the conjugation of the SUMO/Ubiquitin/Nedd8 proteins in a cell of a biological sample the method including: a) a step of contacting a cellular extract of cell with each protein of a subgroup of at least 3 proteins wherein the at least 3 proteins corresponds to the proteins essentially including or only including the sequences SEQ ID NO: 1 to 3, b) a step of simultaneously measuring ubiquitination, sumoylation and neddylation level of each of the at least 3 proteins to obtain a first value for ubiquitin, SUMO and Nedd8.Type: ApplicationFiled: May 28, 2020Publication date: November 10, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Guillaume BOSSIS, Pierre GATEL, Marc PIECHACZYK
-
Publication number: 20220348919Abstract: The invention relates to a nucleic acid molecule comprising: a. a first region comprising a nucleic acid sequence coding for the protein Cyclin D1, also called CCND1, said first region being controlled by means allowing the expression of said protein, and b. at least one second region, said second region comprising essentially a sequence from 14 to 59 nucleic acids, said second region corresponding to a transcribed region of a gene, said second region containing at least a genetic modification compared to the same region of the corresponding wild-type version of said gene, said second region being genetically isolated from the means allowing the expression of said protein such that said second region is not translated into a peptide.Type: ApplicationFiled: May 12, 2022Publication date: November 3, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventor: Frederic BIENVENU
-
Patent number: 11478486Abstract: The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient.Type: GrantFiled: November 14, 2018Date of Patent: October 25, 2022Assignees: INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIERInventors: Céline Gongora, Diego Tosi
-
Extractant for rare earth extraction from aqueous phosphoric acid solutions and method of extraction
Patent number: 11466341Abstract: An extractant which makes it possible to extract both light rare earths and heavy rare earths from an aqueous phosphoric acid solution, likely to be present in this solution, and which is characterised in that it comprises: a compound of formula (I) below: wherein R1 and R2, identical or different, are a hydrocarbon group, saturated or unsaturated, linear or branched, in C6 to C12; R3 is a hydrocarbon group, in C1 to C6, or a hydrocarbon group, saturated or unsaturated, monocyclic, in C3 to C8; R4 and R5, identical or different, are a hydrogen atom or a hydrocarbonate group, saturated or unsaturated, linear or branched, in C2 to C8; and a surfactant. Applications of this extractant include treatment of aqueous solutions from the leaching of natural phosphates by sulphuric acid and aqueous solutions from the leaching of urban minerals by phosphoric acid, in view of making profitable use of the rare earths present in these solutions.Type: GrantFiled: September 14, 2017Date of Patent: October 11, 2022Assignees: COMMISSARIAT Á L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Stéphane Pellet-Rostaing, Julien Rey, Sandrine Dourdain, Guilhem Arrachart, Sefkan Atak -
Publication number: 20220315535Abstract: In vitro or ex vivo methods for screening a quinoline derivative, or anyone of its pharmaceutically acceptable salt, presumed effective in treating and/or preventing an inflammatory disease, the method including: providing an eukaryotic cell, bringing into contact said cell with a quinoline derivative, measuring an expression of miR-124 in the cell, and selecting the candidate presumed effective in treating and/or preventing an inflammatory disease when the level of expression of miR-124 measured is increased relatively to a reference value.Type: ApplicationFiled: May 17, 2022Publication date: October 6, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier SCHERRER, Jamal TAZI
-
Patent number: 11441181Abstract: A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.Type: GrantFiled: January 17, 2014Date of Patent: September 13, 2022Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jamal Tazi, Didier Scherrer, Aude Garcel, Noëlie Campos, Romain Najman, Florence Mahuteau-Betzer